Vivecon (MPC-9055) Clinical Trials

Therapeutic Area: HIV

Phase 1 Clinical Trial

Vivecon™ (MPC-9055) is a potent small-molecule orally bioavailable HIV maturation inhibitor. This first in human study will characterize the safety, tolerability and pharmacokinetic properties of this compound in a single ascending dose study in healthy volunteers.